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Abstract The CD4 receptor synergizes with the T-cell antigen 
receptor (TCR) in helper T-cell activation. However CD4 cross- 
linking in the absence of simultaneous TCR engagement leaves 
the cells primed to activation dependent apoptosis. To assess the 
role of the CD4 associated protein tyrosine kinase p56lck in CD4 
priming to apoptosis we have constructed Jurkat T-cell lines 
stably transfected with a constitutively active form of p56lck. 
These cells were constitutively primed to undergo apoptosis upon 
TCR crosslinking with specific antibodies. In addition the Jurkat 
JCaMl line, which is defective for p56lck expression, was resis- 
tant to TCR induced apoptosis. These data indicate that p56lck 
is required for T-cell apoptosis and that CD4 priming of T-cells 
for antigen dependent apoptosis is due to inappropriate or partial 
activation of the p56lck signal transduction pathway. 
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1. Introduction 
The autocrine growth loop initiated by the expression of 
interleukin-2 (IL-2) and its receptor is a key factor in the com- 
plex process of T-cell activation. IL-2 expression is activated by 
signals derived from the T-cell antigen receptor (TCR) after 
recognition of specific antigen in the context of the major histo- 
compatibility complex (MHC) on the surface of antigen pre- 
senting cells. CD4 or CD8 molecules also play a part in this 
process by interacting with non-polymorphic regions of the 
MHC and thus modulating the TCR derived signals (reviewed 
in [1,2]). These signals are however not sufficient to activate 
IL-2 expression. Accessory signals are required, which are trig- 
gered by the interaction of other surface molecules on the 
antigen presenting cell with their cognate receptors on the T- 
cell and by lymphokine signals derived from the antigen pre- 
senting cell (reviewed in [3,4]). 
In the absence of the complete set of signals required for full 
activation, T-cells may become committed to alternative fates. 
Under certain conditions, T-cell activating signals can trigger 
programmed cell death mediated by apoptosis, a process which 
involves cytoplasm condensation, membrane blebbing and the 
characteristic cleavage of genomic DNA to nucleosome sized 
multimers (reviewed in [5,6]). This process is essential for re- 
moval of potentially self-reactive cells from the immune reper- 
toire. Subversion of this mechanism has recently been impli- 
cated in the drastic reduction of CD4’ T-cells associated with 
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AIDS (reviewed in [7]). Crosslinking of CD4 using Mabs or 
indirectly using HIV gp120 and gpl20-specific antibodies leaves 
the cells primed for subsequent activation dependent apoptosis 
[8,9]. In addition, peripheral T-cells isolated from HIV positive 
patients who have high levels of circulating gpl20 and gp120- 
specific antibodies are hypersensitive to apoptosis induced by 
TCR engagement [ 10,111. It has been suggested that sequestra- 
tion of CD4 by crosslinking such that it cannot participate to 
productive TCR interaction with peptide-MHC complexes is 
responsible for this priming for apoptotic cell death [8]. 
The cytoplasmic domain of CD4 interacts with the src family 
protein tyrosine kinase (PTK) p561ck, which plays a critical role 
in T-cell activation [ 12,131. CD4 crosslinking with specific Mab 
results in the activation of p561ck [14], raising the question of 
the role of this activity in CD4 priming to TCR induced apop- 
tosis. To address this question, we constructed Jurkat T-cell 
lines stably transfected with a constitutively active form of 
p561ck. These cells were hypersensitive to apoptosis induced by 
crosslinking with TCR specific antibodies. Conversely, the Jur- 
kat line JCaMl, which is defective for p561ck expression [15], 
was resistant to TCR induced apoptosis. These data suggest 
that p561ck is a key signalling molecule not only in activation, 
but also in apoptosis of T lymphocytes. 
2. Experimental 
2.1. Plasmids and antibodies 
NF-AT/CAT contains a trimer of the NF-AT binding site of the IL-2 
promoter upstream of the CAT gene [16]. To construct stable transfec- 
tants an EcoRI fragment containing the cDNA encoding F5051ck 
[17,18] was cloned into the Xbal site of the neo vector RcCMV (Invitro- 
gen), after filling with Klenow polymerase. IgG from 0KT3 (ATCC) 
hybridoma supernatants were purified on Mabtrap (Pharmacia, LKB, 
Uppsala, Sweden). BMA031 Mab [19] was kindly provided by R. 
Kurrle. a-p561ck polyclonal antibodies were a generous gift of R.M. 
Perlmutter. a-p59fyn polyclonal antibodies and a-phosphotyrosine 
Mab were purchased from Upstate Biotechnology Inc., Boston, 
2.2. Transfections and CAT assays 
Transient transfections, activations and CAT assays were carried out 
as described [20] using IO6 cells per sample and 0.551 pg reporter 
plasmid per sample. Thin-layer chromatograms were scanned and 
chloramphenicol acetylation was quantitated using a phosphorimager 
(Molecular Dynamics, Sunnyvale, CA). To generate stable transfec- 
tants 10’ cells exponentially growing cells were pelleted, washed in PBS 
then resuspended in ice-cold cytomix as described by van den Hoff et 
al. [21]. 10 pg plasmid DNA were added and cells were electroporated 
at 300 V, 960 fiF using a Bio-Rad electroporator. Cells were kept on 
ice for 5 min then diluted to 20 ml with RPM1 lO%FCS and allowed 
to recover ON. They were then pelleted, resuspended at 2 x 105/ml in 
the same medium supplemented-with supernatant from exponentially 
growing cells and 1 me/ml G418 (Gibco) and mated in 96-well mates. 
Cells were kept under-selection for 4-6 weeks till the appearance of 
colonies. 
2.3. Immunoprecipitations, immunoblots and kinase assays 
Cells were lysed and subjected to immunoprecipitation as described 
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[22]. In vitro kinase assays using [Y-~‘P]ATP were carried out in the 
absence of exogenous substrate for 4 min at RT on washed immunopre- 
cipitates in phosphorylation buffer (25 mM HEPES pH 7.2, 100 mM 
NaCl, 5 mM MgCI,). Alternatively, 10 pug acid-denatured enolase per 
sample were used as exogenous substrate in 20 mM Tris pH 7.2,10 mM 
MgCl,, 10 mM MnCl,, 5 yM ATP. “P-labeled proteins were resolved 
by SDS-PAGE and visualised and quantitated using a phosphorimager 
(Molecular Dynamics, Sunnyvale, CA). Immunoblots were carried out 
using a chemiluminescence detection kit (ECL, Amersham). 
2.4. Apoptosis 
Activation by cross-linking of mouse Mabs to TCR/CD3 was carried 
out by incubation of the cells for 30 min at 4°C with 1 pg/ml Mab 
followed by transfer of the cells to wells which had been precoated ON 
with cc-mouse antibodies at 4”C, washed in PBS and blocked for 1 h 
with RPMI-lO%FCS at 37°C. Analysis of DNA fragmentation was 
carried out by electrophoresis on 2% agarose gels in Loehning buffer 
of DNA extracted from lo6 cells as described by Newell et al. [S]. Gels 
were subsequently transferred to nitrocellulose filters and hybridized to 
total human DNA 3*P-labeled by random priming. Quantitation of 
individual bands was performed using a phosphorimager (Molecular 
Dynamics, Sunnyvale, CA). Apoptotic cells were identified and quanti- 
tated by flow cytometry by their subdiploid DNA content using propo- 
dium iodide staining according to the procedure described by Nicoletti 
et al. [23]. 
3. Results and discussion 
Jurkat T cells were stably transfected with a gene coding for 
a constitutively active form of p561ck with a Tyr to Phe substi- 
tution at position 505 (F5051ck). Mutation of the 505 regulatory 
tyrosine results in a molecule that cannot be downregulated and 
has a constitutively enhanced kinase activity [ 17,181. Transient 
transfection experiments in Jurkat cells have shown that this 
constitutively active mutant triggers a calcium dependent gene 
activating signal which synergizes with phorbol ester to activate 
the NF-AT transcription factor [24]. Functional F5051ck activ- 
ity was assayed in individual G418 resistant clones by transient 
transfection with a NF-AT dependent reporter construct [16]. 
Three independent clones were found in which PMA induced 
NF-AT activation (Table 1). 
Fig. 1 presents the characterization of clone 11, which gave 
the strongest NF-AT/CAT activity. Immunoblots of cell ex- 
tracts with a-p561ck antiserum revealed a modest increase in the 
amount of total p561ck in the transfected line compared to the 
parental Jurkat line. Accordingly, in vitro kinase assays of 
p561ck immunoprecipitates showed a twofold increase in 
p561ck activity in the F5051ck line (Fig. 1A). Immunoblots with 
a-phosphotyrosine antibodies revealed however a massive in- 
crease in phosphoproteins in the F5051ck line (Fig. 1A). In 
addition, as we have recently reported [25], increased p59fyn 
activity in the absence of stimulation was found in this line (Fig. 
Table 1 
Selection of Jurkat clones expressing F505lck 
Clone CAT (fold stimulation) 
F505lck(l) 0 
F505lck(5) 0.6 
F505lck(7) 0 
F505lck(8) 3.1 
F505lck(9) 2.8 
F505lck(ll) 10.8 
[‘4C]Chloramphenicol acetylation in CAT assays of F505lck clones 
after transient transfection with NF-AT/CAT and activation with 
PMA. 
_+-P56lCk 
-p5sfyn 
-endase 
3.9x 
Fig. 1. Characterization of F505lck Jurkat clone 11. (A) Immunoblot 
ofkxtracts of Jurkat cells and of a stable transfectant clone expressing 
F5051ck (clone 11) resolved bv SDS-PAGE and immunoblotted with 
an a-phosphotyrosine Mab (tip) or with a-p56lck polyclonal antibod- 
ies (middle). The bottom panel shows ‘*P incorporation into enolase in 
in vitro kinase assays of p56lck-specific immunoprecipitates from the 
same cells. (B) In vitro kinase assays of p59fyn-specific immunoprecip- 
itates from non activated Jurkat cells and F505lck clone 11 in the 
absence (top) or in the presence (bottom) of enolase as substrate. 32P- 
labeled proteins were resolved by SDS-PAGE and visualised and quan- 
titated using a phosphorimager. The migration of molecular weight 
markers is indicated. 
1B). Thus low constitutive expression of p56lck activity results 
in the accumulation of significant amounts of phosphotyrosine 
and p59fyn activity. 
Apoptosis can be induced in T-cells by crosslinking the TCRl 
CD3 complex by Mabs [26]. Antibodies against different mole- 
cules in the complex have however different effects. Mabs 
which recognize components of the CD3 complex have signifi- 
cant apoptosis inducing activity whereas Mabs which recognize 
epitopes in the invariant region of the TCR$ chain have very 
little apoptosis inducing activity. Prior CD4 crosslinking has no 
effect on the apoptosis induced by a-CD3 Mab however this 
treatment primes the cells for apoptosis induced by subsequent 
crosslinking of the TCR with a-TCRcta Mab [8,9]. The differ- 
ence between the effects of the a-CD3 and a-TCRc@ Mabs is 
not clear. It is generally believed however that Mabs against the 
TCRa/? chain deliver a signal qualitatively more similar to 
antigen. 
We have tested the response of the F5051ck stably transfected 
lines to crosslinking with a-CD3 or ol-TCRc@ Mabs. The re- 
sults are shown in Fig. 2. As expected, TCR crosslinking on the 
parental Jurkat line with a-CD3 Mab resulted in massive apop- 
tosis as evidenced by the characteristic degradation of genomic 
DNA to nucleosome-sized multimers, whereas crosslinking 
with a-TCRc@ Mab caused only minor DNA degradation. 
Two clones transfected with the plasmid vector showed DNA 
fragmentation similar to the parental line. On the other hand, 
all three F5051ck expressing clones showed substantial in- 
creases in TCRolg induced DNA fragmentation. Quantitation 
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Fig. 2. F5051ck Jurkat cells are hypersensitive to TCR dependent apop- 
tosis. Ethidium bromide staining of agarose gels of DNA extracted 
respectively from three F5051ck clones (A) and from Jurkat parental 
cells and two neomycin resistant clones (B). 1, non activated; 2, acti- 
vated with a-CD3 Mab; 3, activated with anti-TCRc@ Mab. 
of subdiploid (apoptotic) cells by flow cytometry revealed that 
apoptosis induced by a-TCRc@ Mab was consistently higher 
in F5051ck transfected cells than in control cells (Table 2). The 
level of surface expression of the TCR complex was similar in 
all clones tested (data not shown) and showed no correlation 
with the levels of TCR-induced apoptosis. The quantitation by 
flow cytometry was confirmed by hybridization of blotted aga- 
rose gels similar to those shown in Fig. 2 with “P-labeled total 
human DNA and counting the radioactivity in individual bands 
Table 2 
Quantitation of apoptosis in F5051ck Jurkat cells 
Cell line 
Jurkat 
neo (4) 
neo (12) 
F5051ck(8) 
F5051ck(ll) 
Apoptosis (TCR/CD3) ? S.D. (n) 
0.62 + 0.106(5) 
0.47 f 0.035(3) 
0.43 f 0.035(3) 
0.99 + 0.113(3) 
1.08 ? 0.120(5) 
corresponding to nucleosome-sized multimers in the low molec- 
ular weight region of the gels (data not shown). 
p561ck activation thus enhances the sensitivity of Jurkat cells 
to apoptosis induced by TCR crosslinking. We questioned 
whether this activity was an essential component for induction 
of apoptosis using a Jurkat cell variant (JCaMl) defective for 
functional p561ck expression [15]. As shown in Fig. 3 neither 
TCR nor CD3 cross-linking induced detectable DNA fragmen- 
tation in JCaMl cells. The apoptotic mechanism was however 
intact since treatment with the calcium ionophore A23187 
alone, which is known to induce apoptosis in most T-cells [27], 
resulted in DNA fragmentation to similar levels in both Jurkat 
and JCaMl cells. It could be argued that a_TCR and cl-CD3 
Mab failed to induce apoptosis in JCaMl cells simply because 
the TCR fails to signal. However, TCR signaling in JCaMl 
cells is not completely defective since a-CD3 Mabs induce weak 
signaling [15]. More importantly, the TCR retained the ability 
to signal normally to the Ras regulatory pathway through 
phosphorylation of the She adaptor protein (Baldari et al., in 
preparation). Hence p561ck activation appears to play a key 
role in transducing signals involved not only in priming to 
apoptosis by CD4, but also in triggering of apoptosis by the 
TCRICD3 complex. 
These data suggest that CD4 priming of T-cells for antigen 
dependent apoptosis is due to the inappropriate or partial acti- 
vation of the p561ck signal transduction pathway. Support for 
this hypothesis comes from the observations that IL-2 also 
primes T-cells to activation dependent apoptosis [28], and that 
p561ck, which is associated with the P-chain of the IL-2 recep- 
tor, is activated by IL-2/IL-2 receptor interaction [29]. Further- 
more, cyclosporin A, which blocks p561ck signaling [24], also 
blocks TCR induced apoptosis [30]. Very little is known about 
signal transduction pathways leading to activation induced ap- 
optosis in lymphocytes (reviewed in [6]). Our data suggest that, 
in the absence of additional survival signals required for prolif- 
eration, p561ck activation plays a key role in this process. 
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